Problems in specific brain cells linked to Fragile X symptoms
Cortical Interneuron Dysfunction in Fragile X Syndrome
This research looks at whether problems with certain brain cells called parvalbumin interneurons lead to sensory sensitivity in people with Fragile X Syndrome.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11284007 on NIH RePORTER |
What this research studies
Researchers use a well-established Fragile X mouse model to trace how parvalbumin interneurons are born, migrate, mature, and connect into the sensory cortex. They combine birth-dating, anatomy, two-photon and functional recordings, and repetitive sensory (whisker) stimulation to link cellular changes to tactile defensiveness. The team also tests whether briefly boosting interneuron activity can correct circuit dysfunction and reduce maladaptive avoidance behaviors in mice. Findings aim to point toward cellular targets that could guide future human treatments.
Who could benefit from this research
Good fit: People with Fragile X Syndrome—especially those who experience sensory hypersensitivity—are the population most likely to benefit from eventual therapies informed by this work.
Not a fit: People without Fragile X Syndrome or whose symptoms are unrelated to sensory processing are unlikely to benefit directly from this project in the near term.
Why it matters
Potential benefit: If successful, this work could point to new therapies that target interneurons to reduce sensory hypersensitivity in people with Fragile X Syndrome.
How similar studies have performed: Previous mouse studies have shown that restoring interneuron activity can improve sensory circuit function, but translating those approaches to safe and effective human treatments remains unproven.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Portera-Cailliau, Carlos — University of California Los Angeles
- Study coordinator: Portera-Cailliau, Carlos
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.